UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934
Date
of Report (Date of earliest event reported)
March
12, 2007
Bovie
Medical Corporation
(Exact
name of registrant as specified in its
charter)
|
Delaware
|
0-12183
|
11-2644611
|
|
(State
or other jurisdiction
|
(Commission
|
(IRS
Employer
|
|
Of
incorporation)
|
File
Number)
|
Identification
No.)
|
734
Walt Whitman Road, Melville, New York
11747
(Address
of principal executive offices) (Zip
Code)
Registrant's
telephone number, including area code
(631)
421-5452
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended
to
simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
] Written communications pursuant to Rule 425 under the Securities Act 17
CFR
230.425)
[
] Soliciting material pursuant to Rule l4a-12 under the Exchange
Act
(17
CFR 240.l4a-12)
[
] Pre-commencement communications pursuant to Rule l4d- 2(b) under the Exchange
Act (17 CFR 240. l4d- 2(b)
[
] Pre-commencement communications pursuant to Rule 13 e-4( c) under the Exchange
Act (17 CFR 240.13 e-4( c)
Item
8.01 OTHER
EVENTS
SEE
ATTACHED EXHIBIT
EXHIBITS:
99.1
Press
Release March 12, 2007 announcing Bovie Medical Corporation’s completion of
development of monopolar and bipolar forceps at its Canadian
subsidiary.
BOVIE
MEDICAL CORPORATION
By:
Andrew
Makrides
/S/
ANDREW MAKRIDES
President
BOVIE
MEDICAL CORPORATION ANNOUNCES COMPLETION OF DEVELOPMENT OF MONOPOLAR AND
BIPOLAR
MODULAR FORCEPS; EXPECTED TO SIGNIFICANTLY IMPACT FUTURE
GROWTH
Melville,
New York, March 12, 2007 - Bovie Medical Corporation (the “Company”) (Amex:
BVX), a manufacturer and marketer of electrosurgical products, today announced
that it’s Canadian subsidiary has completed the prototypes of the Company’s
Polaris™ line of monopolar and bipolar modular forceps. The
patent pending Polaris™ line offers all the benefits of the Company’s recently
FDA cleared Modular Ergonomic Grip (MEG) forceps line while expanding the
cartridge offerings to bipolar endoscopic cartridges (jaws and electrodes),
between 4-12 mm in diameter.
The
new
Polaris™ line for the first time offers advantages to the end user that allow
for monopolar and bipolar energy combined with intelligent feedback from
an
electrosurgical generator. The Polaris™ handle will also accommodate a wide
array of possible applications in either monopolar or bipolar surgeries,
thus
serving endoscopic needs in multiple endoscopic fields. Bipolar vessel sealing
and coagulation is one of the fastest, most lucrative growing markets in
Endoscopy, estimated to be over $500 million in revenues worldwide.
The
company anticipates submitting the Polaris™ line to the Food and Drug
Administration for 510(k) review during the second half of 2007.
Commenting
on the Polaris™ line, Andrew Makrides, president and CEO of Bovie Medical
stated, “One of our main goals as a company is to develop innovative
technologies that are complementary to our core electrosurgery business.
When we
made the decision to acquire Lican Development, Ltd. last fall, we were
confident their instrument technologies would lead to several high margin
new
products. The early indications from potential customers for our new
instruments, with the Polaris™ line, in particular, generating substantial
interest have been promising. It is conceivable that the Polaris™ line of
instruments has the possibility to significantly impact future revenues while
becoming the mainstay of our electrosurgical product line.”
This
document may contain some forward looking statements, particularly regarding
operational prospects in 2007 and beyond, which involve a number of risks
and
uncertainties that could cause actual results to differ materially. These
risks
are listed from time to time in the Company’s SEC filings.
Contact
Information:
Investor
Relations:
John
Aneralla
Buttonwood
Advisory Group, Inc. Phone (800) 940-9087